06.26.2026

FDA Approves Viridian's Lumvoa for Thyroid Eye Disease (TED)

Key Takeaways The FDA has approved Lumvoa (veligrotug-vvze) for thyroid eye disease (TED), giving Viridian Therapeutics its first commercial product Approval was based on the phase 3 THRIVE and THRIVE-2 trials, which met all primary and secondary endpoints in active and chronic TED Lumvoa becomes the second FDA-approved pharmacologic treatment for TED Viridian plans an immediate US launch The FDA has approved Viridian Therapeutics' Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED). The approval of Lumvoa, a new insulin-like growth factor-1 receptor (IGF-1R) antagonist, marks the first FDA-approved therapy for TED with labeling that includes data in both active and chronic disease.